Anti-IL-5 Vaccination Dampens Allergen-Specific IgE Levels and Modulates IL-4 and IL-5 Th2 Cytokines in Skin Allergy of Mice and Horses.

1. Mitson‐Salazar A, Prussin C. Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease. Frontiers in Medicine 4 (2017): 165.
   pmc: PMC5635264pubmed: 29057225
2. Prussin C. Cytokine Flow Cytometry: Understanding Cytokine Biology at the Single‐Cell Level. Journal of Clinical Immunology 17, no. 3 (1997): 195–204.
   pubmed: 9168399
3. Prussin C, Lee J, Foster B. Eosinophilic Gastrointestinal Disease and Peanut Allergy Are Alternatively Associated With IL‐5+ and IL‐5(−) T(H)2 Responses. Journal of Allergy and Clinical Immunology 124, no. 6 (2009): 1326–1332.e6.
   pmc: PMC2994258pubmed: 20004787
4. Wagner B. IgE in Horses: Occurrence in Health and Disease. Veterinary Immunology and Immunopathology 132, no. 1 (2009): 21–30.
   pubmed: 19819562
5. Schaffartzik A, Hamza E, Janda J, Crameri R, Marti E, Rhyner C. Equine Insect Bite Hypersensitivity: What Do We Know?. Veterinary Immunology and Immunopathology 147, no. 3–4 (2012): 113–126.
   pubmed: 22575371
6. Woodfolk J A. T‐Cell Responses to Allergens. Journal of Allergy and Clinical Immunology 119, no. 2 (2007): 280–294; quiz 95‐6.
   pubmed: 17291848
7. Blanchard C, Rothenberg M E. Basic Pathogenesis of Eosinophilic Esophagitis. Gastrointestinal Endoscopy Clinics of North America 18, no. 1 (2008): 133–143. x.
   pmc: PMC2194642pubmed: 18061107
8. Strath M, Dent L, Sanderson C. Infection of IL5 Transgenic Mice With Mesocestoides Corti Induces Very High Levels of IL5 but Depressed Production of Eosinophils. Experimental Hematology 20, no. 2 (1992): 229–234.
   pubmed: 1544392
9. Kopf M, Brombacher F, Hodgkin P D. IL‐5‐Deficient Mice Have a Developmental Defect in CD5+ B‐1 Cells and Lack Eosinophilia but Have Normal Antibody and Cytotoxic T Cell Responses. Immunity 4, no. 1 (1996): 15–24.
   pubmed: 8574848
10. Collins P D, Marleau S, Griffiths‐Johnson D A, Jose P J, Williams T J. Cooperation Between Interleukin‐5 and the Chemokine Eotaxin to Induce Eosinophil Accumulation In Vivo. Journal of Experimental Medicine 182, no. 4 (1995): 1169–1174.
    pmc: PMC2192289pubmed: 7561691
11. Robinson D S. Mepolizumab for Severe Eosinophilic Asthma. Expert Review of Respiratory Medicine 7, no. 1 (2013): 13–17.
    pubmed: 23362812
12. Leon‐Ferre R A, Weiler C R, Halfdanarson T R. Hypereosinophilic Syndrome Presenting as an Unusual Triad of Eosinophilia, Severe Thrombocytopenia, and Diffuse Arterial Thromboses, With Good Response to Mepolizumab. Clinical Advances in Hematology & Oncology 11, no. 5 (2013): 317–319.
    pubmed: 23880717
13. Ortega H G, Yancey S W, Mayer B. Severe Eosinophilic Asthma Treated With Mepolizumab Stratified by Baseline Eosinophil Thresholds: A Secondary Analysis of the DREAM and MENSA Studies. Lancet Respiratory Medicine 4, no. 7 (2016): 549–556.
    pubmed: 27177493
14. Perez de Llano L A, Dacal Rivas D, Cosio B G. Mepolizumab and Reslizumab, Two Different Options for Severe Asthma Patients With Prior Failure to Omalizumab. Allergy 75, no. 4 (2020): 940–942.
    pubmed: 31483864
15. Wechsler M E, Hickey L, Garin M, Chauhan A. Efficacy of Reslizumab Treatment in Exacerbation‐Prone Patients With Severe Eosinophilic Asthma. Journal of Allergy and Clinical Immunology: In Practice 8, no. 10 (2020): 3434–3442.e4.
    pubmed: 32562877
16. Gauvreau G. M., Sehmi R., FitzGerald J. M., et al., “Benralizumab for Allergic Asthma: A Randomised, Double‐Blind, Placebo‐Controlled, Trial,” European Respiratory Journal 64 (2024): 2400512.
    pmc: PMC11391094pubmed: 39060015
17. Pini L., Bagnasco D., Beghe B., et al., “Unlocking the Long‐Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three‐Year Real‐Life Study,” Journal of Clinical Medicine 13, no. 10 (2024): 3013.
    pmc: PMC11122375pubmed: 38792553
18. Rothenberg M. E., Dellon E. S., Collins M. H., et al., “Eosinophil Depletion With Benralizumab for Eosinophilic Esophagitis,” New England Journal of Medicine 390, no. 24 (2024): 2252–2263.
    pubmed: 38924732
19. Fettelschoss‐Gabriel A., Fettelschoss V., Thoms F., et al., “Treating Insect‐Bite Hypersensitivity in Horses With Active Vaccination Against IL‐5,” Journal of Allergy and Clinical Immunology 142, no. 4 (2018): 1194–1205.e3.
    pubmed: 29627082
20. Fettelschoss‐Gabriel A., Fettelschoss V., Olomski F., et al., “Active Vaccination Against Interleukin‐5 as Long‐Term Treatment for Insect‐Bite Hypersensitivity in Horses,” Allergy 74, no. 3 (2019): 572–582.
    pmc: PMC6587569pubmed: 30402930
21. Schwarz E. J. F., Keller G., Rhiner T., et al., “Phenotypic Shift of an Inflammatory Eosinophil Subset Into a Steady‐State Resident Phenotype After 2 Years of Vaccination Against IL‐5 in Equine Insect Bite Hypersensitivity,” Veterinary Sciences 11 (2024): 476.
    pmc: PMC11512288pubmed: 39453068
22. Rhiner T., Fettelschoss V., Schoster A., Birkmann K., and Fettelschoss‐Gabriel A., “Targeting Eosinophils by Active Vaccination Against Interleukin‐5 Reduces Basophil Counts in Horses With Insect Bite Hypersensitivity in the 2nd Year of Vaccination,” Veterinary Journal 288 (2022): 105896.
    pubmed: 36126798
23. Jonsdottir S., Fettelschoss V., Olomski F., et al., “Safety Profile of a Virus‐Like Particle‐Based Vaccine Targeting Self‐Protein Interleukin‐5 in Horses,” Vaccine 8, no. 2 (2020): 213.
    pmc: PMC7349629pubmed: 32397549
24. Zou Y., Sonderegger I., Lipowsky G., et al., “Combined Vaccination Against IL‐5 and Eotaxin Blocks Eosinophilia in Mice,” Vaccine 28, no. 18 (2010): 3192–3200.
    pubmed: 20189490
25. Li M., Hener P., Zhang Z., Kato S., Metzger D., and Chambon P., “Topical Vitamin D3 and Low‐Calcemic Analogs Induce Thymic Stromal Lymphopoietin in Mouse Keratinocytes and Trigger an Atopic Dermatitis,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 31 (2006): 11736–11741.
    pmc: PMC1544239pubmed: 16880407
26. Li M., Hener P., Zhang Z., Ganti K. P., Metzger D., and Chambon P., “Induction of Thymic Stromal Lymphopoietin Expression in Keratinocytes Is Necessary for Generating an Atopic Dermatitis Upon Application of the Active Vitamin D3 Analogue MC903 on Mouse Skin,” Journal of Investigative Dermatology 129, no. 2 (2009): 498–502.
    pubmed: 18650845
27. Schmitz N., Dietmeier K., Bauer M., et al., “Displaying Fel d1 on Virus‐Like Particles Prevents Reactogenicity Despite Greatly Enhanced Immunogenicity: A Novel Therapy for Cat Allergy,” Journal of Experimental Medicine 206, no. 9 (2009): 1941–1955.
    pmc: PMC2737174pubmed: 19667059
28. Leuthard D. S., Duda A., Freiberger S. N., et al., “Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen‐Specific Immunotherapy Protect From IgE‐Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling,” Journal of Immunology 200, no. 9 (2018): 3151–3159.
    pmc: PMC5911931pubmed: 29592962
29. Schaffartzik A., Marti E., Torsteinsdottir S., Mellor P. S., Crameri R., and Rhyner C., “Selective Cloning, Characterization, and Production of the Culicoides Nubeculosus Salivary Gland Allergen Repertoire Associated With Equine Insect Bite Hypersensitivity,” Veterinary Immunology and Immunopathology 139, no. 2–4 (2011): 200–209.
    pubmed: 21071100
30. Jonsdottir S., Torsteinsdottir S., Svansson V., et al., “Comparison of Recombinant Culicoides Allergens Produced in Different Expression Systems for IgE Serology of Insect Bite Hypersensitivity in Horses of Different Origins,” Veterinary Immunology and Immunopathology 238 (2021): 110289.
    pubmed: 34214910
31. Peeters L. M., Janssens S., Schaffartzik A., Marti E., and Buys N., “Evaluation of IgE Levels Against Culicoides Nubeculosus Allergens in Belgian Warmblood Horses,” Communications in Agricultural and Applied Biological Sciences 77, no. 1 (2012): 218–222.
    pubmed: 22558784
32. van der Meide N. M., Savelkoul H. F., Meulenbroeks C., Ducro B. J., and Tijhaar E., “Evaluation of a Diagnostic ELISA for Insect Bite Hypersensitivity in Horses Using Recombinant Obsoletus Complex Allergens,” Veterinary Journal 200, no. 1 (2014): 31–37.
    pubmed: 24703873
33. Cahenzli J., Koller Y., Wyss M., Geuking M. B., and McCoy K. D., “Intestinal Microbial Diversity During Early‐Life Colonization Shapes Long‐Term IgE Levels,” Cell Host & Microbe 14, no. 5 (2013): 559–570.
    pmc: PMC4049278pubmed: 24237701
34. Jonsdottir S., Hamza E., Janda J., et al., “Developing a Preventive Immunization Approach Against Insect Bite Hypersensitivity Using Recombinant Allergens: A Pilot Study,” Veterinary Immunology and Immunopathology 166, no. 1–2 (2015): 8–21.
    pubmed: 26004943
35. Pantelyushin S., Rhiner T., Jebbawi F., et al., “Interleukin 5‐Dependent Inflammatory Eosinophil Subtype Involved in Allergic Insect Bite Hypersensitivity of Horses,” Allergy 78, no. 11 (2023): 3020–3023.
    pubmed: 37605865
36. Nunomura S., Ito R., Nanri Y., et al., “Novel Mechanisms by Which Benralizumab Suppresses IgE Expression in Human B Cells in Humanized Mice,” Allergy 78, no. 12 (2023): 3271–3273.
    pubmed: 37814937
37. Contoli M., Santus P., Menzella F., et al., “Effects of Anti‐IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients: A Real‐Life Multicentre Study (BIONIGE),” Clinical and Translational Allergy 12, no. 4 (2022): e12143.
    pmc: PMC8988861pubmed: 35423001
38. Hitoshi Y., Yamaguchi N., Mita S., et al., “Distribution of IL‐5 Receptor‐Positive B Cells. Expression of IL‐5 Receptor on Ly‐1(CD5)+ B Cells,” Journal of Immunology 144, no. 11 (1990): 4218–4225.
    pubmed: 1692859
39. Hitoshi Y., Sonoda E., Kikuchi Y., Yonehara S., Nakauchi H., and Takatsu K., “IL‐5 Receptor Positive B Cells, but Not Eosinophils, Are Functionally and Numerically Influenced in Mice Carrying the X‐Linked Immune Defect,” International Immunology 5, no. 9 (1993): 1183–1190.
    pubmed: 8241057
40. Kolbeck R., Kozhich A., Koike M., et al., “MEDI‐563, a Humanized Anti‐IL‐5 Receptor Alpha mAb With Enhanced Antibody‐Dependent Cell‐Mediated Cytotoxicity Function,” Journal of Allergy and Clinical Immunology 125, no. 6 (2010): 1344–1353.e2.
    pubmed: 20513525
41. Takatsu K., “Interleukin‐5 and IL‐5 Receptor in Health and Diseases,” Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 87, no. 8 (2011): 463–485.
    pmc: PMC3313690pubmed: 21986312
42. Gorski S. A., Lawrence M. G., Hinkelman A., et al., “Expression of IL‐5 Receptor Alpha by Murine and Human Lung Neutrophils,” PLoS One 14, no. 8 (2019): e0221113.
    pmc: PMC6695150pubmed: 31415658
43. Dahl C., Hoffmann H. J., Saito H., and Schiotz P. O., “Human Mast Cells Express Receptors for IL‐3, IL‐5 and GM‐CSF; a Partial Map of Receptors on Human Mast Cells Cultured In Vitro,” Allergy 59, no. 10 (2004): 1087–1096.
    pubmed: 15355468
44. Wilson T. M., Maric I., Shukla J., et al., “IL‐5 Receptor Alpha Levels in Patients With Marked Eosinophilia or Mastocytosis,” Journal of Allergy and Clinical Immunology 128, no. 5 (2011): 1086–1092.e1–3.
    pmc: PMC3205313pubmed: 21762978
45. Steven Eck M. C., Sinibaldi D., White W., et al., “Benralizumab Effect on Blood Basophil Counts in Adults With Uncontrolled Asthma,” European Respiratory Journal 44 (2014): P297.
46. Lommatzsch M., Marchewski H., Schwefel G., Stoll P., Virchow J. C., and Bratke K., “Benralizumab Strongly Reduces Blood Basophils in Severe Eosinophilic Asthma,” Clinical and Experimental Allergy 50, no. 11 (2020): 1267–1269.
    pubmed: 32762056
47. Jebbawi F., Chemnitzer A., Dietrich M., et al., “Cytokines and Chemokines Skin Gene Expression in Correlation With Immune Cells in Blood and Severity in Equine Insect Bite Hypersensitivity,” Frontiers in Immunology 15 (2024): 1414891.
    pmc: PMC11284025pubmed: 39076967
48. Raza F., Babasyan S., Larson E. M., Freer H. S., Schnabel C. L., and Wagner B., “Peripheral Blood Basophils Are the Main Source for Early Interleukin‐4 Secretion Upon In Vitro Stimulation With Culicoides Allergen in Allergic Horses,” PLoS One 16, no. 5 (2021): e0252243.
    pmc: PMC8153460pubmed: 34038479
49. Guo L., Hu‐Li J., and Paul W. E., “Probabilistic Regulation of IL‐4 Production in Th2 Cells: Accessibility at the Il4 Locus,” Immunity 20, no. 2 (2004): 193–203.
    pubmed: 14975241
50. Zhu J., “T Helper 2 (Th2) Cell Differentiation, Type 2 Innate Lymphoid Cell (ILC2) Development and Regulation of Interleukin‐4 (IL‐4) and IL‐13 Production,” Cytokine 75, no. 1 (2015): 14–24.
    pmc: PMC4532589pubmed: 26044597
51. Akbari O., Stock P., Meyer E., et al., “Essential Role of NKT Cells Producing IL‐4 and IL‐13 in the Development of Allergen‐Induced Airway Hyperreactivity,” Nature Medicine 9, no. 5 (2003): 582–588.
    pubmed: 12669034
52. Yoshimoto T., “The Hunt for the Source of Primary Interleukin‐4: How we Discovered That Natural Killer T Cells and Basophils Determine T Helper Type 2 Cell Differentiation In Vivo,” Frontiers in Immunology 9 (2018): 716.
    pmc: PMC5924770pubmed: 29740428
53. Noval Rivas M., Burton O. T., Oettgen H. C., and Chatila T., “IL‐4 Production by Group 2 Innate Lymphoid Cells Promotes Food Allergy by Blocking Regulatory T‐Cell Function,” Journal of Allergy and Clinical Immunology 138, no. 3 (2016): 801–811.e9.
    pmc: PMC5014699pubmed: 27177780
54. Pelly V. S., Kannan Y., Coomes S. M., et al., “IL‐4‐Producing ILC2s Are Required for the Differentiation of T(H)2 Cells Following Heligmosomoides Polygyrus Infection,” Mucosal Immunology 9, no. 6 (2016): 1407–1417.
    pmc: PMC5257265pubmed: 26883724
55. McLeod J. J., Baker B., and Ryan J. J., “Mast Cell Production and Response to IL‐4 and IL‐13,” Cytokine 75, no. 1 (2015): 57–61.
    pmc: PMC4532630pubmed: 26088754
56. Weiss D. L. and Brown M. A., “Regulation of IL‐4 Production in Mast Cells: A Paradigm for Cell‐Type‐Specific Gene Expression,” Immunological Reviews 179 (2001): 35–47.
    pubmed: 11292025
57. Bjerke T., Gaustadnes M., Nielsen S., et al., “Human Blood Eosinophils Produce and Secrete Interleukin 4,” Respiratory Medicine 90, no. 5 (1996): 271–277.
    pubmed: 9499811
58. Goh Y. P., Henderson N. C., Heredia J. E., et al., “Eosinophils Secrete IL‐4 to Facilitate Liver Regeneration,” Proceedings of the National Academy of Sciences of the United States of America 110, no. 24 (2013): 9914–9919.
    pmc: PMC3683773pubmed: 23716700
59. Guth C., Schumacher P. P., Vijayakumar A., et al., “Eosinophils Are an Endogenous Source of Interleukin‐4 During Filarial Infections and Contribute to the Development of an Optimal T Helper 2 Response,” Journal of Innate Immunity 16, no. 1 (2024): 159–172.
    pmc: PMC10932553pubmed: 38354709
60. Kasaian M. T., Clay M. J., Happ M. P., Garman R. D., Hirani S., and Luqman M., “IL‐4 Production by Allergen‐Stimulated Primary Cultures: Identification of Basophils as the Major IL‐4‐Producing Cell Type,” International Immunology 8, no. 8 (1996): 1287–1297.
    pubmed: 8918698
61. Min B., Prout M., Hu‐Li J., et al., “Basophils Produce IL‐4 and Accumulate in Tissues After Infection With a Th2‐Inducing Parasite,” Journal of Experimental Medicine 200, no. 4 (2004): 507–517.
    pmc: PMC2211939pubmed: 15314076
62. van Panhuys N., Prout M., Forbes E., Min B., Paul W. E., and Le Gros G., “Basophils Are the Major Producers of IL‐4 During Primary Helminth Infection,” Journal of Immunology 186, no. 5 (2011): 2719–2728.
    pmc: PMC3488853pubmed: 21270410
63. Nagata K., Hirai H., Tanaka K., et al., “CRTH2, an Orphan Receptor of T‐Helper‐2‐Cells, Is Expressed on Basophils and Eosinophils and Responds to Mast Cell‐Derived Factor(s),” FEBS Letters 459, no. 2 (1999): 195–199.
    pubmed: 10518017
64. Sullivan B. M., Liang H. E., Bando J. K., et al., “Genetic Analysis of Basophil Function In Vivo,” Nature Immunology 12, no. 6 (2011): 527–535.
    pmc: PMC3271435pubmed: 21552267
65. Eckl‐Dorna J., Ellinger A., Blatt K., et al., “Basophils Are Not the Key Antigen‐Presenting Cells in Allergic Patients,” Allergy 67, no. 5 (2012): 601–608.
    pmc: PMC4601523pubmed: 22335568
66. Kitzmuller C., Nagl B., Deifl S., et al., “Human Blood Basophils Do Not Act as Antigen‐Presenting Cells for the Major Birch Pollen Allergen Bet v 1,” Allergy 67, no. 5 (2012): 593–600.
    pubmed: 22188598
67. Sokol C. L., Chu N. Q., Yu S., Nish S. A., Laufer T. M., and Medzhitov R., “Basophils Function as Antigen‐Presenting Cells for an Allergen‐Induced T Helper Type 2 Response,” Nature Immunology 10, no. 7 (2009): 713–720.
    pmc: PMC3252751pubmed: 19465907
68. Wagner B., Stokol T., and Ainsworth D. M., “Induction of Interleukin‐4 Production in Neonatal IgE+ Cells After Crosslinking of Maternal IgE,” Developmental and Comparative Immunology 34, no. 4 (2010): 436–444.
    pubmed: 19995577
69. Del Prete G., Maggi E., Parronchi P., et al., “IL‐4 Is an Essential Factor for the IgE Synthesis Induced In Vitro by Human T Cell Clones and Their Supernatants,” Journal of Immunology 140, no. 12 (1988): 4193–4198.
    pubmed: 2967330
70. Pene J., Rousset F., Briere F., et al., “IgE Production by Normal Human Lymphocytes Is Induced by Interleukin 4 and Suppressed by Interferons Gamma and Alpha and Prostaglandin E2,” Proceedings of the National Academy of Sciences of the United States of America 85, no. 18 (1988): 6880–6884.
    pmc: PMC282082pubmed: 2970644
71. Pene J., Rousset F., Briere F., et al., “IgE Production by Normal Human B Cells Induced by Alloreactive T Cell Clones Is Mediated by IL‐4 and Suppressed by IFN‐Gamma,” Journal of Immunology 141, no. 4 (1988): 1218–1224.
    pubmed: 3135324
72. Sarfati M. and Delespesse G., “Possible Role of Human Lymphocyte Receptor for IgE (CD23) or Its Soluble Fragments in the In Vitro Synthesis of Human IgE,” Journal of Immunology 141, no. 7 (1988): 2195–2199.
    pubmed: 2971721
73. Vercelli D., Jabara H. H., Arai K., and Geha R. S., “Induction of Human IgE Synthesis Requires Interleukin 4 and T/B Cell Interactions Involving the T Cell Receptor/CD3 Complex and MHC Class II Antigens,” Journal of Experimental Medicine 169, no. 4 (1989): 1295–1307.
    pmc: PMC2189234pubmed: 2522501
74. Lebman D. A. and Coffman R. L., “Interleukin 4 Causes Isotype Switching to IgE in T Cell‐Stimulated Clonal B Cell Cultures,” Journal of Experimental Medicine 168, no. 3 (1988): 853–862.
    pmc: PMC2189023pubmed: 3049907
75. Strom L., Laurencikiene J., Miskiniene A., and Severinson E., “Characterization of CD40‐Dependent Immunoglobulin Class Switching,” Scandinavian Journal of Immunology 49, no. 5 (1999): 523–532.
    pubmed: 10320646
76. Mandler R., Chu C. C., Paul W. E., Max E. E., and Snapper C. M., “Interleukin 5 Induces S Mu‐S Gamma 1 DNA Rearrangement in B Cells Activated With Dextran‐Anti‐IgD Antibodies and Interleukin 4: A Three Component Model for Ig Class Switching,” Journal of Experimental Medicine 178, no. 5 (1993): 1577–1586.
    pmc: PMC2191240pubmed: 8228808
77. Mizoguchi C., Uehara S., Akira S., and Takatsu K., “IL‐5 Induces IgG1 Isotype Switch Recombination in Mouse CD38‐Activated sIgD‐Positive B Lymphocytes,” Journal of Immunology 162, no. 5 (1999): 2812–2819.
    pubmed: 10072528
78. Coffman R. L., Lebman D. A., and Rothman P., “Mechanism and Regulation of Immunoglobulin Isotype Switching,” Advances in Immunology 54 (1993): 229–270.
    pubmed: 8379463
79. Stavnezer J., “Antibody Class Switching,” Advances in Immunology 61 (1996): 79–146.
    pubmed: 8834495
80. Kracker S. and Radbruch A., “Immunoglobulin Class Switching: In Vitro Induction and Analysis,” Methods in Molecular Biology 271 (2004): 149–159.
    pubmed: 15146119
81. Snapper C. M., Rosas F. R., Zelazowski P., et al., “B Cells Lacking RelB Are Defective in Proliferative Responses, but Undergo Normal B Cell Maturation to Ig Secretion and Ig Class Switching,” Journal of Experimental Medicine 184, no. 4 (1996): 1537–1541.
    pmc: PMC2192806pubmed: 8879226
82. Jabara H., Laouini D., Tsitsikov E., et al., “The Binding Site for TRAF2 and TRAF3 but Not for TRAF6 Is Essential for CD40‐Mediated Immunoglobulin Class Switching,” Immunity 17, no. 3 (2002): 265–276.
    pubmed: 12354380
83. Purkerson J. M. and Isakson P. C., “Interleukin 5 (IL‐5) Provides a Signal That Is Required in Addition to IL‐4 for Isotype Switching to Immunoglobulin (Ig) G1 and IgE,” Journal of Experimental Medicine 175, no. 4 (1992): 973–982.
    pmc: PMC2119169pubmed: 1552290
84. Kung T. T., Stelts D. M., Zurcher J. A., et al., “Involvement of IL‐5 in a Murine Model of Allergic Pulmonary Inflammation: Prophylactic and Therapeutic Effect of an Anti‐IL‐5 Antibody,” American Journal of Respiratory Cell and Molecular Biology 13, no. 3 (1995): 360–365.
    pubmed: 7654390
85. Brostrom H., Larsson A., and Troedsson M., “Allergic Dermatitis (Sweet Itch) of Icelandic Horses in Sweden: An Epidemiological Study,” Equine Veterinary Journal 19, no. 3 (1987): 229–236.
    pubmed: 3608962
86. Halldorsdottir S., Lazary S., Gunnarsson E., and Larsen H. J., “Distribution of Leucocyte Antigens in Icelandic Horses Affected With Summer Eczema Compared to Non‐Affected Horses,” Equine Veterinary Journal 23, no. 4 (1991): 300–302.
    pubmed: 1915232
87. Lange S., Hamann H., Deegen E., Ohnesorge B., and Distl O., “Investigation of the Prevalence of Summer Eczema in Icelandic Horses in Northern Germany,” Berliner und Münchener Tierärztliche Wochenschrift 118, no. 11–12 (2005): 481–489.
    pubmed: 16318272
88. Bjornsdottir S., Sigvaldadottir J., Brostrom H., Langvad B., and Sigurdsson A., “Summer Eczema in Exported Icelandic Horses: Influence of Environmental and Genetic Factors,” Acta Veterinaria Scandinavica 48, no. 1 (2006): 3.
    pmc: PMC1513129pubmed: 16987399
89. Torsteinsdottir S., Scheidegger S., Baselgia S., et al., “A Prospective Study on Insect Bite Hypersensitivity in Horses Exported From Iceland Into Switzerland,” Acta Veterinaria Scandinavica 60, no. 1 (2018): 69.
    pmc: PMC6215642pubmed: 30390694

Citations

1. Wichtowska A, Olejnik M. Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.. Int J Mol Sci 2025 Nov 13;26(22).
   doi: 10.3390/ijms262210990pubmed: 41303472google scholar: lookup